Despite the DLBCL heterogeneity, the neoplastic cells typically express pan-B-cell markers CD19, CD20, CD22, CD79a, PAX5 (1), paving the way for the introduction of targeted therapies. Here, CD19 is linked to diffuse large B-cell lymphoma.